New Delhi metallo-β-lactamase-1 in Enterobacteriaceae: Emerging resistance

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 1, 2011, Pages 59-64

  Pillai, Dylan R ^a,b,c   McGeer, Allison ^a,b,c   Low, Donald E ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b PUBLIC HEALTH ONTARIO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; GENTAMICIN; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; POLYMYXIN DERIVATIVE; QUINOLONE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIUM CULTURE; CANADA; DNA SEQUENCE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; GENE IDENTIFICATION; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIA; KLEBSIELLA PNEUMONIAE; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NDM 1 GENE; NEPHROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROSTHESIS INFECTION; REVIEW; STRAIN IDENTIFICATION; TRAVEL;

EID: 78651421248     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101487     Document Type: Review

References (33)

1. Clinical and Laboratory Standards Institute. Performance. Standards for antimicrobial susceptibility testing: twentieth informational supplement update M100-S20-U. Wayne (PA): The Institute; 2010.
2. Ofner-Agostini M, Simor A, Mulvey M, et al. Risk factors for and outcomes associated with clinical isolates of Escherichia coli and Klebsiella species resistant to extended-spectrum cephalosporins among patients admitted to Canadian hospitals. Can J Infect Dis MedMicrobiol 2009;20:e43-8.
3. Giakkoupi P, Xanthaki A, Kanelopoulou M, et al. VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003;41:3893-6.
4. Health Protection Agency. Healthcare-associated infections and antimicrobial resistance: 2009/10. London (UK): The Agency; 2010. Available: www.hpa.org.uk/web/HPAwebfile/HPAweb-C 1281954479045 (accessed 2010 Dec 10).
5. Pillai DR, Melano R, Rawte P, et al. Klebsiella pneumoniae car- bapenemase, Canada. Emerg Infect Dis 2009;15:827-9.
6. Toye B, Krajden S, Fuksa M, et al. Carbapenem resistance in Canada. CMAJ 2009;180:1225-6.
7. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046-54.
8. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.
9. Deshpande P, Rodrigues C, Shetty A, et al. New Delhi metallo- beta-lactamase (NDM-1) in Enterobacteriaceae: Treatment options with carbapenems compromised. J Assoc Physicians India 2010;58:147-9.
10. Detection of Enterobacteriaceae isolates carrying metallo-β- lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep 2010;59:750.
11. Melano R, Longtin J, Pillai D. Alert: potential emergence of new carbapenemase-producing organisms in Ontario, Canada. QMP-LSNews May 2010;(150):5. Available: http://qmp-ls.org/pub-resources/publications/qmpls- news/pdf/qmplsnews150.pdf (accessed 2010 Dec 10).
12. Leverstein-van Hall MA, Stuart JC, Voets GM, et al. [Carbapenem-resistant Klebsiella pneumoniae following foreign travel] [Article in Dutch]. Ned Tijdschr Geneeskd 2010; 154:A2013.
13. Poirel L, Lagrutta E, Taylor P, et al. Emergence of metallo-β- lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother 2010;11:4914-16.
14. Mulvey MR, Grant JM, Plewes K, et al. New Delhi metallo-β- lactamase in Kelbsiella pneumoniae and Escherichia coli, Canada. Emerg Infect Dis 2011 Nov. 11 [Epub ahead of print]
15. Laupland KB, Church DL, Vidakovich J, et al. Community- onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008;57:441-8.
16. Deloitte Center for Health Solutions. Medical tourism: update and implications - 2009 report. Washington (DC): The Center; 2009. Available: http://www.deloitte.com/assets/Dcom-UnitedStates Local%20Assest/Documents/us- chs-MedicalTourism-102609.pdf (accessed 2010 Dec 10).
17. Report of the Council on Medical Service: medical care outside the United States, AMA Council on Medical Service Report 1 (A-08). Chicago (IL): Council on Medical Service; 2008. Available: www.ama-assn.org/ama1/pub/upload/mm/372/a- 08cms1 .pdf (accessed 2010 Dec 10).
18. Eggertson L. Wait-list weary Canadians seek treatment abroad. CMAJ 2006;174:1247.
19. Turner L. Medical tourism: family medicine and international health-related travel. Can Fam Physician 2007;53:1639-41.
20. Woodford N, Eastaway AT, Ford M, et al. Comparison of BD Phoenix, Vitek 2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae. J Clin Microbiol 2010;48: 2999-3002.
21. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006;12:1209-13.
22. Public Health Agency of Canada. Guidance: infection prevention and control measures for healthcare workers in all healthcare settings: carbapenem-resistant gram-negative bacilli. Ottawa (ON): The Agency; 2010. Available: www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/ipcm-mpci-eng.php (accessed 2010 Dec. 7).
23. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256-60.
24. Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010;16:102-11.
25. Provincial Infection Control Network - BC. Antibiotic resistant organisms prevention and control guidelines, November 2008. Available: www.bccdc.ca/NR/rdonlyres/F4154D6F-DB88-4D2C-9973-8421F3B934AF/0/ InfectionControl-GF-ARO-Guidelines-November2008.pdf (accessed 2010 Dec 10).
26. Webster PC. Global action urged in response to new breed of drug-resistant bacteria. CMAJ 2010 Sept. 20 [Epub ahead of print]. Available: www.cmaj.ca/cgi/rapidpdf/cmaj.109-3675v1 (accessed 2010 Dec 10).
27. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30:972-6.
28. Landman D, Georgescu C, Martin DA, et al. Polymyxins revisited. Clin Microbiol Rev 2008 ;21:449-65.
29. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65: 1019-27.
30. Souli M, Kontopidou FV, Papadomichelakis E, et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek university hospital. Clin Infect Dis 2008;46:847-54.
31. Kelesidis T, Karageorgopoulos DE, Kelesidis I, et al. Tigecy- cline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008;62:895-904.
32. U.S. Food and Drug Administration. FDA drug safety podcast for healthcare professionals: increased risk of death with Tygacil (tige- cycline) compared to other antibiotics used to treat similar infections. Silver Spring (MD): US Department of Health and Human Services; 2010. Available: www.fda.gov/Drugs/ DrugSafety DrugSafetyPodcasts/ucm224896.htm (accessed 2010 Dec 10).
33. Cobo J, Morosini MI, Pintado V, et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008;60:319-22.